VTR

Ventas
D

VTR

Arincen48/100B

If you had invested in Ventas ago, it would be worth $2,314 today, against $4,096 in SPY and $6,368 in QQQ.

ArincenArincen ScoreBeta

48/100

Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.

Profitability2

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Cash10

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Valuation—

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Growth8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Financial strength0

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Shareholders4

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Figures to FY2025; the price as of today.

Ventas key facts

Style
Growth stock · 7.6/10Growth 7.6 · Value 4.0 · Dividend 5.5
Day range
89.270 – 90.100
52-week range
73.820 – 101.600
Market capitalization
47.49B USD
P/E
166.31
PEG ratio
4.79
EPS
0.54
Div Yield
2.32%
EPS growth forecast (FY2026)
+2.3%
Volume
7,161
Beta
0.77
ESG score
60.4/100Environment 57 · Social 58 · Governance 65
Sector
Real Estate
Industry
REIT - Healthcare Facilities
CEO
Debra A. Cafaro
Employees
542
IPO date
5 May 1997

Ventas earnings

Next earnings · Q4 FY2026
EPS estimate
0.15 USD
Revenue estimate
1.83B USD
Last quarter · Q3 FY2026
EPS0.13Missed -19.8%Revenue1.83BBeat +3.6%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q1 FY20270.17——+54.55%1.89B——+13.82%
Q4 FY20260.15——+1.33%1.83B——+16.62%
Q3 FY20260.160.13-19.80%-7.14%1.77B1.83B+3.57%+23.02%
Q2 FY20260.140.14-1.62%-6.67%1.68B1.73B+2.91%+21.73%
Q1 FY20260.120.11-10.50%0.00%1.59B1.66B+4.51%+22.01%
Q4 FY20250.100.15+48.96%+15.38%1.50B1.57B+4.09%+21.67%
Q3 FY20250.090.14+52.19%-82.50%1.44B1.49B+3.62%+20.44%
Q2 FY20250.850.15-82.35%+200.00%1.38B1.42B+3.07%+18.31%

Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved

Ventas analyst forecast

12-month price target
99.45 USD
+10.73%

Analysts' 1-year price targets range from 88.00 to 110.00, with an average of 99.45.

Past year
1-year forecast
Strong sellStrong buy
Buy
13 ratings
Buy
10
Hold
3
Sell
0

12-month price target

Highest target110.00
Average target99.45
Lowest target88.00
Current price89.81

Ventas valuation

Price to earnings ratio (TTM)
166.31
Forward P/E (FY2026)
159.65
Price to sales (TTM)
7.00
Price to book
3.00
EV / EBITDA (TTM)
23.19

Capital structure

Market capitalization
47.49B USD
+
Total debt
12.67B USD
−
Cash and short-term investments
202.01M USD
=
Enterprise value
59.96B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)77.56————
FY2027 (est.)104.4777.56———
FY2026 (est.)159.65104.47———
Now (TTM)166.31109.447.003.0023.19
FY2025140.69137.526.042.8121.30
FY2024294.45121.504.922.2520.37
FY2023-498.40493.994.452.1119.53
FY2022-346.54340.134.071.6619.46
FY2021393.23340.135.111.8021.39

Ventas against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Omega Healthcare Investors, Healthpeak Properties, Welltower, American Healthcare REIT, CareTrust REIT, and Healthcare Realty Trust, the US REIT - Healthcare Facilities companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • Gross marginLowest in 5 years-5.9%
    -5.9%45.4%
    Against its peers: 6 of 7Peers' median 30.8%
  • Operating marginHighest in 5 years14.2%
    9.2%14.2%
    Against its peers: 4 of 7Peers' median 13.7%
  • Net marginHighest in 5 years4.3%
    -1.1%4.3%
    Against its peers: 4 of 7Peers' median 5.9%
  • Return on equityHighest in 5 years2.0%
    -0.5%2.0%
    Against its peers: 5 of 7Peers' median 2.2%
  • Free cash flow marginHighest in 5 years22.0%
    19.1%22.0%
    Against its peers: 5 of 7Peers' median 35.5%
  • Revenue growthHighest in 5 years18.5%
    0.9%18.5%
    Against its peers: 3 of 7Peers' median 11.6%
  • EPS growthHighest in 5 years184.2%
    -200.0%184.2%
    Against its peers: 1 of 5Peers' median 6.8%
  • Debt to EBITDALowest in 5 years5.90×
    5.90×8.33×
    Against its peers: 4 of 7Peers' median 5.98×
  • Current ratioAbove its median0.96
    0.611.04
    Against its peers: 6 of 7Peers' median 1.65

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

Ventas growth and profitability

Revenue (TTM)
6.78B USD
Net income (TTM)
265.60M USD
Gross margin
-0.89%
Operating margin
12.17%
Net margin
3.91%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY20255.83B+18.47%251.38M+209.76%-5.90%14.17%4.31%2.24B+22.97%
FY20244.92B+9.48%81.15M—42.59%13.83%1.65%1.82B+7.08%
FY20234.50B+8.93%-40.97M—43.06%9.24%-0.91%1.70B+13.37%
FY20224.13B+7.87%-47.45M-196.81%44.71%11.72%-1.15%1.50B+1.37%
FY20213.83B+0.86%49.01M-88.84%45.44%11.01%1.28%1.48B-16.42%

Ventas revenue breakdown

By product

FY2025
Senior Living Operations: 74.0%Outpatient Medical And Research Portfolio: 15.5%Triple Net Leased Properties: 10.4%74.0%Senior Living Operations15.5%Outpatient Medical And Research Portfolio10.4%Triple Net Leased Properties
SegmentRevenueShare of revenueChange on the year
Senior Living Operations4.28B74.0%+26.8%
Outpatient Medical And Research Portfolio897.90M15.5%—
Triple Net Leased Properties601.58M10.4%-3.3%

By region

FY2025
United States: 89.3%Canada: 9.5%United Kingdom: 1.2%89.3%United States9.5%Canada1.2%United Kingdom
RegionRevenueShare of revenueChange on the year
United States5.21B89.3%+19.3%
Canada552.92M9.5%+5.0%
United Kingdom71.23M1.2%+131.7%

Ventas dividends

Annual dividend
2.08 USD
Dividend yield (indicated)
2.32%
Payout ratio (FFO)
53.28%
Years of dividend growth
2
Frequency
Quarterly
Last payment
0.52 USD
Last ex-dividend date
30 Sept 2026
Last payment date
15 Oct 2026

Dividends per share

Year2025202420232022202120202019201820172016
Dividends per share1.891.801.801.801.802.493.173.162.332.97

Ventas financial health

Cash and short-term investments
202.01M USD
Total debt
12.67B USD
Net cash
-12.47B USD
Current ratio
0.44
Debt to equity
0.80
Piotroski score
6 / 9
Altman Z-score
1.92

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY2025741.07M13.22B1.28B
FY2024897.85M13.74B1.05B
FY2023508.79M13.69B860.46M
FY2022122.56M12.49B898.03M
FY2021149.73M12.22B840.84M

Ventas ownership

Institutions
111.05%
Institutional holders
980 (+24)
Free float
99.46%

Who owns the shares

Institutions 100.0% Others 0.0%
As of 30 Jun 2026

Shares free to trade

Free float 525.97M shares ·99.5% Closely held 2.85M shares ·0.5%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

QuarterPurchasesSalesShares acquiredShares disposed of
Q4 2026007.39K0.00
Q3 20260017.77K0.00
Q2 20261127.84K7.37K
Q1 202605473.96K342.73K

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY2025455.08M462.62M+11.11%
FY2024411.77M416.37M+2.64%
FY2023401.81M405.67M+8.65%
FY2022373.37M373.37M-3.35%
FY2021382.79M386.30M+2.60%

Source: Financial Modeling Prep

Related Instruments

Title: Ventas

Sector: Real Estate
Industry: REIT - Healthcare Facilities
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.

Common questions about Ventas stock